1. Balancing the Risks and Benefits of Multidrug Regimens in the Clinical Management of Nontuberculous Mycobacterial Lung Disease

2. Program Overview

3. NTM Lung Disease Introduction

4. Radiographic Manifestations

5. Predisposing Factors

6. Managing NTM Lung Disease Can Be Challenging

7. Determining Who To Treat

8. Guideline-Based Recommendations for Treating NTM Lung Disease

9. Standard Treatment for MAC, Macrolide-Susceptible Disease

10. Standard Treatment for MAC, Macrolide-Susceptible Disease (cont)

11. When Is Treatment NOT Indicated?

12. Treatment-Related AEs Standard Care

13. Monitoring Response

14. Unresolved Questions

15. Unresolved Questions (cont)

16. Unresolved Questions (cont)

17. Benefits of Inhaled Therapies

18. ALIS Overview

19. Phase 2 Trial ALIS

20. Treatment-Related AEs ALIS vs Placebo

21. Findings ALIS Phase 2 Trial

22. Phase 3 Trial CONVERT

23. Findings CONVERT Trial

24. Treatment-Related AEs CONVERT Trial

25. Who Best Benefits From ALIS?

26. Bedaquiline Overview

27. Case Series Bedaquiline

28. Treatment-Related AEs Bedaquiline

29. Oxazolidinones Tedizolid, Linezolid Overview

30. Clofazimine Overview

31. Treatment-Related AEs Clofazimine

32. Nitric Oxide Overview

33. Concluding Remarks

34. Abbreviations